142 related articles for article (PubMed ID: 8785474)
1. Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery.
Zhao Q; Temsamani J; Agrawal S
Antisense Res Dev; 1995; 5(3):185-92. PubMed ID: 8785474
[TBL] [Abstract][Full Text] [Related]
2. beta-Cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence.
Abdou S; Collomb J; Sallas F; Marsura A; Finance C
Arch Virol; 1997; 142(8):1585-602. PubMed ID: 9672621
[TBL] [Abstract][Full Text] [Related]
3. Uptake, intracellular distribution, and stability of oligodeoxynucleotide phosphorothioate by Schistosoma mansoni.
Tao LF; Marx KA; Wongwit W; Jiang Z; Agrawal S; Coleman RM
Antisense Res Dev; 1995; 5(2):123-9. PubMed ID: 7580116
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
5. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
[TBL] [Abstract][Full Text] [Related]
6. Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs.
Zhao Q; Temsamani J; Iadarola PL; Agrawal S
Biochem Pharmacol; 1996 Nov; 52(10):1537-44. PubMed ID: 8937468
[TBL] [Abstract][Full Text] [Related]
7. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells.
Iversen PL; Zhu S; Meyer A; Zon G
Antisense Res Dev; 1992; 2(3):211-22. PubMed ID: 1490072
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide--amino-beta-cyclodextrins and adamantane conjugates.
Habus I; Zhao Q; Agrawal S
Bioconjug Chem; 1995; 6(4):327-31. PubMed ID: 7578351
[TBL] [Abstract][Full Text] [Related]
9. Digoxigenin-labeled phosphorothioate oligonucleotides: a new tool for the study of cellular uptake.
Tarrasón G; Bellido D; Eritja R; Vilaró S; Piulats J
Antisense Res Dev; 1995; 5(3):193-201. PubMed ID: 8785475
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
[No Abstract] [Full Text] [Related]
11. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides.
Khaled Z; Benimetskaya L; Zeltser R; Khan T; Sharma HW; Narayanan R; Stein CA
Nucleic Acids Res; 1996 Feb; 24(4):737-45. PubMed ID: 8604318
[TBL] [Abstract][Full Text] [Related]
12. Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo.
Desjardins J; Mata J; Brown T; Graham D; Zon G; Iversen P
J Drug Target; 1995; 2(6):477-85. PubMed ID: 7773609
[TBL] [Abstract][Full Text] [Related]
13. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.
Giles RV; Spiller DG; Grzybowski J; Clark RE; Nicklin P; Tidd DM
Nucleic Acids Res; 1998 Apr; 26(7):1567-75. PubMed ID: 9512525
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
Lisziewicz J; Sun D; Weichold FF; Thierry AR; Lusso P; Tang J; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7942-6. PubMed ID: 8058738
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric and microscopic characterization of the uptake and distribution of phosphorothioate oligonucleotides in human keratinocytes.
Wingens M; van Hooijdonk CA; de Jongh GJ; Schalkwijk J; van Erp PE
Arch Dermatol Res; 1998 Mar; 290(3):119-25. PubMed ID: 9558486
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes.
Miyano-Kurosaki N; Barnor JS; Takeuchi H; Owada T; Nakashima H; Yamamoto N; Matsuzaki T; Shimada F; Takaku H
Antivir Chem Chemother; 2004 Mar; 15(2):93-100. PubMed ID: 15185727
[TBL] [Abstract][Full Text] [Related]
17. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.
Thierry AR; Dritschilo A
Nucleic Acids Res; 1992 Nov; 20(21):5691-8. PubMed ID: 1454532
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
19. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.
Marcusson EG; Bhat B; Manoharan M; Bennett CF; Dean NM
Nucleic Acids Res; 1998 Apr; 26(8):2016-23. PubMed ID: 9518498
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.
Kang H; Fisher MH; Xu D; Miyamoto YJ; Marchand A; Van Aerschot A; Herdewijn P; Juliano RL
Nucleic Acids Res; 2004; 32(14):4411-9. PubMed ID: 15316104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
